Septerna to Present at Jefferies Global Healthcare Conference
Septerna (NASDAQ: SEPN), a biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's CEO and Co-founder, Jeffrey Finer, M.D., Ph.D., will deliver a presentation on Thursday, June 5, 2025, at 3:45 p.m. ET in New York. Interested parties can access a live webcast of the presentation through the company's website or the provided link, with the recording remaining available for at least 30 days afterward.
Septerna (NASDAQ: SEPN), un'azienda biotecnologica specializzata nella scoperta di farmaci mirati ai recettori accoppiati a proteine G (GPCR), ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Il CEO e cofondatore dell'azienda, Jeffrey Finer, M.D., Ph.D., terr脿 una presentazione il gioved矛 5 giugno 2025 alle 15:45 ET a New York. Gli interessati potranno seguire la diretta streaming della presentazione tramite il sito web dell'azienda o il link fornito, con la registrazione disponibile per almeno 30 giorni successivi.
Septerna (NASDAQ: SEPN), una empresa biotecnol贸gica enfocada en el descubrimiento de f谩rmacos dirigidos a los receptores acoplados a prote铆nas G (GPCR), ha anunciado su participaci贸n en la pr贸xima Jefferies Global Healthcare Conference. El CEO y cofundador de la compa帽铆a, Jeffrey Finer, M.D., Ph.D., realizar谩 una presentaci贸n el jueves 5 de junio de 2025 a las 3:45 p.m. ET en Nueva York. Los interesados podr谩n acceder a una transmisi贸n en vivo a trav茅s del sitio web de la empresa o mediante el enlace proporcionado, con la grabaci贸n disponible durante al menos 30 d铆as despu茅s.
Septerna (NASDAQ: SEPN)電� G 雼氨歆� 鞐瓣舶 靾橃毄觳�(GPCR) 鞎诫 氚滉铂鞐� 欷戩爯鞚� 霊� 靸濍獏瓿淀暀 須岇偓搿�, 雼り岸撵槫電� Jefferies Global Healthcare Conference鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� CEO鞚挫瀽 瓿惦彊 彀诫鞛愳澑 Jeffrey Finer, M.D., Ph.D.臧赌 2025雲� 6鞗� 5鞚� 氇╈殧鞚� 鞓ろ泟 3鞁� 45攵�(霃欕秬 響滌鞁�) 雺挫殨鞐愳劀 氚滍憸毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 甏�鞁� 鞛堧姅 攵勲摛鞚� 須岇偓 鞗轨偓鞚错姼 霕愲姅 鞝滉车霅� 毵來伂毳� 韱淀暣 氚滍憸 鞁れ嫓臧� 鞗轨簮鞀ろ姼毳� 鞁滌箔頃� 靾� 鞛堨溂氅�, 雲鬼檾 鞓侅儊鞚� 斓滌唽 30鞚缄皠 雼れ嫓氤搓赴搿� 鞝滉车霅╇媹雼�.
Septerna (NASDAQ : SEPN), une soci茅t茅 de biotechnologie sp茅cialis茅e dans la d茅couverte de m茅dicaments ciblant les r茅cepteurs coupl茅s aux prot茅ines G (GPCR), a annonc茅 sa participation 脿 la prochaine Jefferies Global Healthcare Conference. Le PDG et cofondateur de l'entreprise, Jeffrey Finer, M.D., Ph.D., pr茅sentera une intervention le jeudi 5 juin 2025 脿 15h45 (heure de l'Est) 脿 New York. Les personnes int茅ress茅es pourront suivre la pr茅sentation en direct via le site web de la soci茅t茅 ou le lien fourni, avec un enregistrement disponible pendant au moins 30 jours apr猫s la diffusion.
Septerna (NASDAQ: SEPN), ein Biotechnologieunternehmen, das sich auf die Entdeckung von Wirkstoffen gegen G-Protein-gekoppelte Rezeptoren (GPCR) spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angek眉ndigt. Der CEO und Mitbegr眉nder des Unternehmens, Jeffrey Finer, M.D., Ph.D., wird am Donnerstag, den 5. Juni 2025, um 15:45 Uhr ET in New York eine Pr盲sentation halten. Interessierte k枚nnen die Pr盲sentation live 眉ber die Unternehmenswebseite oder den bereitgestellten Link verfolgen; die Aufzeichnung steht mindestens 30 Tage danach zur Verf眉gung.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 3:45 p.m. ET in New York.
A live webcast of the presentation will be available and in the investors section of the company鈥檚 website at . The webcast will be archived for at least 30 days following the presentation.
About Septerna
Septerna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform鈩�. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visit聽.
Investor Contact:
Renee Leck
THRUST Strategic Communications
FAQ
When is Septerna (SEPN) presenting at the Jefferies Global Healthcare Conference 2025?
Who will represent Septerna (SEPN) at the Jefferies Healthcare Conference 2025?
How can investors watch Septerna's (SEPN) presentation at the Jefferies Conference?
What is Septerna's (SEPN) main business focus?
